Salubris Biotherapeutics Reports the EMA’s Approval to Conduct P-I Study of JK06 for Treating Solid Tumors
Shots:
- The EMA has granted approval to conduct the P-I basket study of JK06 (FIC quadrivalent, biparatopic ADC) for the treatment of various solid tumors expressing 5T4
- The P-I will be an open-label, dose-escalation & expansion trial to evaluate the safety, pharmacokinetics & preliminary efficacy among 155 individuals (expected). It will be initiated during Q3’24
- JK06 works by targeting 5T4 with an MMAE payload. It showed picomolar affinity, quick internalization, strong efficacy as well as a favorable safety profile in preclinical studies
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
